# A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

> **NCT03745820** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 195 (actual)

## Conditions studied

- Cognitive Impairment Associated With Schizophrenia

## Interventions

- **DRUG:** BIIB104
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03745820
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-04-07
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745820, "A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03745820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*